$RFL News
Last published 1w ago
- 1w agoRFLRFL-WTRafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswireNEWARK, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today announced that it will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on
- 1w agoRFLRafael Holdings, Inc. - PRESS RELEASE, DATED OCTOBER 29, 2026, REPORTING THE RESULTS OF OPERATIONS FOR TEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 8.01 Item 9.01
- 1w agoRFLRFL-WTRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate UpdateGlobeNewswireNEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026. Fiscal 2026 and Recent
- 1w agoRFLRFL-WTRafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type CGlobeNewswireNDA supported by the Phase 3 TransportNPC™ study, data from earlier clinical studies, and an overall survival analysis versus external registry controls Remibetadex has received Orphan Drug, Fast Track and Rare
- 3mo agoERNARFLErnexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical StageGlobeNewswireSeasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance Appointment further strengthens
- 5mo agoRFLRafael Holdings Reports Third Quarter Fiscal 2026 Financial ResultsGlobeNewswireNEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026. "Yesterday, we were pleased to
- 5mo agoRFLRafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type CGlobeNewswireTopline results are expected to be announced in second half of calendar 2026 The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026 The company has received
- 6mo agoRFLRafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease"GlobeNewswireNEWARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute
- 8mo agoRFLRafael Holdings Reports Second Quarter Fiscal 2026 Financial ResultsGlobeNewswireNEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026. "We remain pleased with the
- 11mo agoRFLRafael Holdings Reports First Quarter Fiscal 2026 Financial ResultsGlobeNewswireNEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025. "We remain pleased with the progress
- 1y agoRFLRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial ResultsGlobeNewswireCyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of
- 1y agoRFLRafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of DirectorsGlobeNewswireNEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to
- 1y agoRFLRafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years OldGlobeNewswireFirst data on treatment of NPC1 with Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients1 showed stabilization or
- 1y agoRFLRafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)GlobeNewswireNEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs
- 1y agoRFLRafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim DataGlobeNewswirePhase 3 TransportNPC study to continue based on the independent DMC review of safety and efficacy data at prespecified 48-week interim analysis Data on the investigational candidate Trappsol® Cyclo™
- 1y agoRFLRafael Holdings Reports Third Quarter Fiscal 2025 Financial ResultsGlobeNewswireNEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025.
- 1y agoRFLRafael Holdings, Inc. Announces Final Results and Closing of Rights OfferingGlobeNewswireNEWARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) announced today the final results and closing of its $25.0 million rights offering (the "Rights Offering"). The subscription
- 1y agoRFLRafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™GlobeNewswireNEWARK, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today provided an update to the subscription rights related to its Public Warrants in connection with its previously announced
- 1y agoRFLRafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™GlobeNewswireNEWARK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced revised subscription rights in connection with its previously announced rights offering. Holders of record as
- 1y agoRFLRafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™GlobeNewswireNEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing
- 1y agoRFLRafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His RoleGlobeNewswireCyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the
- 1y agoCYTHRFLRafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder ApprovalsGlobeNewswireNEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced the closing of their business combination following
- 1y agoCYTHRFLRafael Holdings Reports Second Quarter Fiscal 2025 Financial ResultsGlobeNewswireThe planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo's lead clinical program
- 1y agoCYTHRFLRafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsGlobeNewswireNEWARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the first quarter of fiscal year 2025 ended October 31, 2024. "We anticipate proceeding to a
- 2y agoCYTHRFLRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsGlobeNewswireNEWARK, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the fourth quarter and the full fiscal year ended July 31, 2024. "During fiscal 2024, we
- 2y agoCDESMCCOFSRFLKuehn Law Encourages CDE, SMC, COFS, and RFL Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoCOFSFYBRKAVLRFLKuehn Law Encourages COFS, KAVL, FYBR, and RFL Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoCOFSARCRFLNBYKuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoCYTHRFLRafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger AgreementBusiness WireCyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from
- 2y agoCYTHRFLRafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger AgreementGlobeNewswireCyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the
- 2y agoCYTHRFLRafael Holdings Reports Third Quarter Fiscal 2024 Financial ResultsGlobeNewswireNEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. "During
- 2y agoCYTHRFLCyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1Business WireTransportNPC™ is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for the treatment of Niemann-Pick Disease Type C1 (NPC1) Topline
- 2y agoCYTHRFLRafael Holdings Reports Second Quarter Fiscal 2024 Financial ResultsGlobeNewswireCompany remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Increased ownership in Day Three Labs to a majority interest of 79%
- 2y agoCYTHRFLRafael Holdings Reports First Quarter Fiscal 2024 Financial ResultsGlobeNewswireNEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023. "During fiscal
- 2y agoAMTICYTHRFLCyclo Therapeutics Reports Third Quarter 2023 Financial ResultsBusiness WireStrong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") Merger with Applied Molecular Transport,
- 3y agoCYTHRFLRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial ResultsGlobeNewswireNEWARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the fourth quarter and full year of fiscal 2023 - the three and twelve months ended July 31,
- 3y agoCYTHRFLCyclo Therapeutics Reports Second Quarter 2023 Financial ResultsBusiness WireContinued strong enrollment of pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) on track to complete enrollment by year end
- 3y agoCYTHRFLCyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.Business WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
- 3y agoRFLRafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business UpdateGlobeNewswireNEWARK, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the third quarter of fiscal 2023 for the three months ended April 30, 2023, as well as the nine
- 3y agoCYTHRFLCyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private PlacementBusiness WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
- 3y agoCYTHRFLCyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsBusiness WireCompany on track to complete enrollment in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) by year end 2023 Cyclo
- 3y agoCYTHRFLCyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)Business WireCyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
- 3y agoRFLRafael Holdings Announces up to $5 Million Share Repurchase ProgramGlobeNewswireNEWARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today announced that its Board of Directors has authorized the repurchase of up to $5 million of the Company's Class B common
- 3y agoRFLRafael Holdings Reports Second Quarter Fiscal 2023 Financial ResultsGlobeNewswireNEWARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its second quarter fiscal 2023 financial results for the three months and six months ended January 31, 2023. "Our
- 3y agoRFLRafael Holdings Reports First Quarter Fiscal 2023 Financial ResultsGlobeNewswireNEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022. "We are pleased to have
- 3y agoRFLRafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development ActivitiesGlobeNewswireNEWARK, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today announced its decision to curtail its early-stage development efforts, including pre-clinical research at the Barer Institute in
- 4y agoRFLRafael Holdings Reports Fourth Quarter Fiscal 2022 Financial ResultsGlobeNewswireNEWARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), a holding company with interests in clinical and early-stage pharmaceutical companies, today reported its financial results for the
- 4y agoRFLCornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic CancerGlobeNewswireCranbury, Sept. 28, 2022 (GLOBE NEWSWIRE) -- September 28, 2022 - Cornerstone Pharmaceuticals, Inc., a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the initiation of a Phase 1 clinical tr
- 4y agoRFLRafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public GarageGlobeNewswireNEWARK, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE:RFL), an early-stage novel cancer and immune metabolism therapeutics company, today announced that it has closed on the sale of the building housing its headquarters to affili
- 4y agoRFLCornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract CancerGlobeNewswireCRANBURY, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. ("Cornerstone" or the "Company"), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the successful completion